Article Text

Download PDFPDF
Many challenges of conducting clinical trials in CJD
  1. Brian S Appleby
  1. Correspondence to Dr Brian S Appleby, Departments of Neurology and Psychiatry, Case Western Reserve University School of Medicine, 3619 Park East Drive, Suite 206, Beachwood, OH 44122, USA; bsa35{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Early treatment of patients with specific molecular subtypes of sporadic Creutzfeldt-Jakob disease may affect treatment effects

Sporadic Creutzfeldt-Jakob disease (sCJD) is a fatal, rapidly progressive, neurodegenerative condition caused by prions that has an average survival time of 4–6 months. Unfortunately, clinical treatment trials in sCJD have not been successful including a recent study that evaluated doxycycline.1

In their JNNP paper, Varges et al2 present data on a small randomised double-blind trial as well as an observational study examining the use of doxycycline in patients with sCJD. Compared with the doxycycline study conducted by Haïk and colleagues, this most recent study examined the use of doxycycline in a relatively earlier stage of sCJD by …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles